In addition to integrins, small molecule inhibitors also target ECM‐modifying enzymes, such as LOX, which catalyzes the cross‐linking of collagen and elastin, thereby increasing ECM stiffness—a critical factor in tumor metastasis and fibrosis. The gene discussed is LOX; the disease is neoplasm.